SCHEMBL22060180

SCHEMBL22060180

Cc1ccccc1C(=O)Nc1nc(NCc2ccccc2)nn1-c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.52
MAPK1 P28482 2/20 0.46
DHODH Q02127 4/20 0.46
RAB9A P51151 3/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 2/20 0.46
ALOX15 P16050 1/20 0.46
PKM P14618 1/20 0.46
LMNA P02545 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HIF1A Q16665 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TP53 P04637 1/20 0.43
F2 P00734 2/20 0.43
CDKN1A P38936 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22060684 0.93 MAPK1 (0.54) POLBMAPK1HTTLMNAMEN1
SCHEMBL22060182 0.91 POLB (0.49) POLBMAPK1RAB9AHTTNPC1
SCHEMBL20110246 0.88 MAPK1 (0.56) POLBMAPK1RAB9AHTTNPC1
SCHEMBL22060133 0.87 NR3C1 (0.48) POLBDHODHRAB9AHTTNPC1
SCHEMBL22060189 0.87 MAPK1 (0.47) MAPK1HTTLMNAMEN1KMT2A
SCHEMBL22060343 0.85 KDR (0.45) MAPK1HTTLMNAMEN1KMT2A
SCHEMBL22060150 0.84 CDKN1A (0.49) POLBRAB9ANPC1LMNAMEN1
SCHEMBL22060706 0.83 MAPK1 (0.51) POLBMAPK1RAB9AHTTNPC1
SCHEMBL21064350 0.82 POLB (0.52) POLBMAPK1RAB9AHTTNPC1
SCHEMBL22871704 0.81 MAPK1 (0.53) POLBMAPK1RAB9AHTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210244712-A1 METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION NYSNOBIO IRELAND DAC (IE) 2021-08-12 US disclosed
US-20210230126-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME NYSNOBIO IRELAND DAC (IE) 2021-07-29 US disclosed
US-10889553-B2 Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same NYSNOBIO IRELAND DAC (IE) 2021-01-12 US disclosed
US-20200172497-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME NYSNOBIO IRELAND DAC (IE) 2020-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210244712-A1 METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION TP53, RB1, CDK1 POLB 643/4885MAPK1 723/4885DHODH 1541/4885
US-20200172497-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME ATG7, PINK1, ADRM1 POLB 1629/4885MAPK1 2259/4885DHODH 3445/4885
US-20210230126-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME ATG7, PINK1, ADRM1 POLB 1629/4885MAPK1 2259/4885DHODH 3445/4885
US-10889553-B2 Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same ATG7, PINK1, ADRM1 POLB 1629/4885MAPK1 2259/4885DHODH 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.